UPDATE: BMO Capital Markets Raises PT on Ambit Biosciences Following 2Q13 Operating Results
August 14, 2013 at 11:10 AM EDT
In a report published Wednesday, BMO Capital Markets analyst Jim Birchenough reiterated an Outperform rating on Ambit Biosciences (NASDAQ: AMBI ), and raised the price target from $10.00 to $23.00. In the report, BMO Capital Markets noted, “Ambit Biosciences (AMBI) reported 2Q13 operating results today and provided an update to key